Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
BAT1006
i
Other names:
BAT1006
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Bio-Thera Solutions
Drug class:
HER2 inhibitor
Related drugs:
‹
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
MCLA-128 (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
trastuzumab-strf (8)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
trastuzumab (407)
afatinib (227)
lapatinib (107)
neratinib (102)
pyrotinib (79)
tucatinib (39)
trastuzumab-pkrb (24)
margetuximab-cmkb (18)
poziotinib (17)
MCLA-128 (16)
KN026 (14)
mobocertinib (12)
trastuzumab-dttb (11)
ZW25 (10)
trastuzumab-anns (9)
trastuzumab-dkst (9)
trastuzumab-qyyp (9)
trastuzumab-strf (8)
LZM-005 (8)
PRS-343 (8)
D3L-001 (7)
inetetamab (6)
ASLAN001 (6)
BDTX-189 (5)
AEE788 (4)
MT-5111 (4)
TAS2940 (4)
Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)
MET306 (4)
pertuzumab/trastuzumab/hyaluronidase-zzxf (3)
DZD9008 (3)
trastuzumab-IFN-β mutein (3)
AST-301 (2)
Bay846 (2)
CT-0508 (2)
DF1001 (2)
ER121 (2)
Her-VAXX (2)
trastuzumab/hyaluronidase-oysk (2)
JBJ-08–178–01 (2)
SAR446309 (2)
BDC-1001 (2)
AB-201 (1)
ABL105 (1)
ACE1702 (1)
Hercease (trastuzumab biosimilar) (1)
BAY 2927088 (1)
BAY2701439 (1)
DZD1516 (1)
HERtiCAD (trastuzumab biosimilar) (1)
Hervelous (trastuzumab biosimilar) (1)
EG12014 (trastuzumab biosimilar) (1)
IAH0968 (1)
IMM2902 (1)
MP0274 (1)
SAR443216 (1)
(1)
TX05 (trastuzumab biosimilar) (1)
VRN101099 (1)
ZN-A-1041 (1)
S-222611 (1)
KD019 (1)
ABT-101 (0)
ADG138 (0)
ALT02 (trastuzumab biosimilar) (0)
trastuzumab biosimilar (AP062) (0)
B-Vaxx (0)
BAY2701438 (0)
BMS690514 (0)
CAM-H2 (0)
CAT-179 (0)
CUDC-101 (0)
DA 3111 (trastuzumab biosimilar) (0)
(0)
ELVN-002 (0)
ES2B-C001 (0)
ETBX-021 (0)
(0)
GB235 (0)
HER-2/neu peptide vaccine (0)
HER2 t-haNK (0)
HF158K1 (0)
HLX11 (pertuzumab biosimilar) (0)
Hervycta (trastuzumab biosimilar) (0)
ISB 1302 (0)
JIN-A04 (0)
JNJ-26483327 (0)
OST-HER2 (0)
MBS301 (0)
MM 111 (0)
MP412 (0)
MVA-BN-HER2 (0)
NVL-330 (0)
NeuCeptin (trastuzumab biosimilar) (0)
nelipepimut-S (0)
lapuleucel-T (0)
OS47701 (0)
QP34563457 (0)
ertumaxomab (0)
trastuzumab biosimilar (SIBP-01) (0)
SPH5030 (0)
SSGJ-705 (0)
(0)
Sym013 (0)
TAC100-HER2 (0)
TAK-285 (0)
TAS0728 (0)
TPIV100 (0)
TQB2930 (0)
glycooptimized trastuzumab-GEX (0)
TrastuRel (trastuzumab biosimilar) (0)
Undisclosed HER2Bi-armed ATC (0)
VM 206 (0)
AST1306 (0)
cipatinib (0)
dHER2+AS15 (0)
IBI315 (0)
KBP-5209 (0)
RG6194 (0)
AZD8931 (0)
trastuzumab biosimilar (0)
trastuzumab biosimilar (0)
›
Associations
News
Trials
Filter by
Latest
19d
An Evaluation of BAT 8010 for Injection in Combination With BAT 1006 in Locally Advanced or Metastatic Entities Safety, Tolerability, Pharmacokinetic Profile, and Initial Clinical Efficacy of the Tumor in Patients Multicenter, Open Phase Ib/IIa Clinical Study (clinicaltrials.gov)
P1/2, N=108, Not yet recruiting, Bio-Thera Solutions
19 days ago
New P1/2 trial • Combination therapy • Metastases
|
BAT1006 • BAT8010
7ms
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=37, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting
7 months ago
Enrollment closed • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
9ms
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=38, Recruiting, Bio-Thera Solutions | N=130 --> 38 | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Jun 2023 --> Aug 2024
9 months ago
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
1year
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=130, Recruiting, Bio-Thera Solutions | N=24 --> 130
1 year ago
Enrollment change • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
almost2years
Evaluating the Safety, Tolerability, and Pharmacokinetics of BAT1006 (clinicaltrials.gov)
P1, N=24, Recruiting, Bio-Thera Solutions
almost 2 years ago
New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
BAT1006
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login